Stock Detail
Videos
PolyPid (PYPD) Company Webcast
During this presentation we welcome, PolyPid. PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical...
News
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
PETACH TIKVA, Israel, Dec. 11, 2024 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc....
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
PETACH TIKVA, Israel, Nov. 29, 2024 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notification (the "Notification Letter") from the...
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Last Patient Enrolled for Planned Unblinded Interim Analysis in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 Unblinded Interim Analysis Outcome Expected Later this Quarter SHIELD II Enrollment Completion Expected in December 2024 with Top-Line Results Anticipated in...